[68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review

Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter

[⁶⁸Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review

Am J Nucl Med Mol Imaging. 2020 Dec 15;10(6):349-374. eCollection 2020.

Authors

Frédéric Bois¹, Camille Noirot¹, Sébastien Dietemann¹, Ismini C Mainta¹, Thomas Zilli^{2

3}, Valentina Garibotto^{1

3}, Martin A Walter^{1

3

4}

Affiliations

¹ Division of Nuclear Medicine, Diagnostic Department, University Hospital of Geneva Geneva, Switzerland.
² Division of Radiation Oncology, Oncology Department, University Hospital of Geneva Geneva, Switzerland.
³ Faculty of Medicine, University of Geneva Geneva, Switzerland.
⁴ Center for Biomedical Imaging (CIBM) Lausanne, Switzerland.

PMID: 33329937
PMCID: PMC7724278

Abstract

Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool for managing patients with recurrent prostate cancer, and one of the most frequently employed radiopharmaceuticals is [⁶⁸Ga]Ga-PSMA-11. Herein, we summarize the preclinical development and the clinical applications of [⁶⁸Ga]Ga-PSMA-11 and present side-by-side comparisons with other radiopharmaceuticals or imaging modalities, in order to assist imagers and clinicians in recommending, performing, and interpreting the results of [⁶⁸Ga]Ga-PSMA-11 PET scans in patients with prostate cancer.

Keywords: PSMA; Prostate cancer; molecular imaging; restaging; staging.